LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease - PubMed (original) (raw)
. 2004 Feb 15;103(4):1542-7.
doi: 10.1182/blood-2003-03-0957. Epub 2003 Oct 16.
Affiliations
- PMID: 14563643
- DOI: 10.1182/blood-2003-03-0957
Free article
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease
Aleksandra Petrovic et al. Blood. 2004.
Free article
Abstract
Lymphocyte Peyer patch adhesion molecule (LPAM) or alpha(4)beta(7) integrin is expressed on lymphocytes and is responsible for T-cell homing into gut-associated lymphoid tissues through its binding to mucosal addressin cell adhesion molecule (MAdCAM), which is present on high endothelial venules of mucosal lymphoid organs. We found in murine allogeneic bone marrow transplantation (BMT) models that recipients of alpha(4)beta(7)(-) donor T cells had significantly less graft-versus-host disease (GVHD) morbidity and mortality compared with recipients of alpha(4)beta(7)(+) donor T cells. A kinetic posttransplantation analysis of lymphocytes in the intestines and mesenteric lymph nodes demonstrated a delayed invasion of lower numbers of alpha(4)beta(7)(+) T cells in recipients of alpha(4)beta(7)(-) T cells compared with recipients of alpha(4)beta(7)(+) T cells. Histopathologic analysis of GVHD target organs revealed that recipients of alpha(4)beta(7)(-) T cells developed less GVHD of the intestines and liver, whereas there was no difference in cutaneous and thymic GVHD between recipients of alpha(4)beta(7)(-) or alpha(4)beta(7)(+) T cells. Finally, we found that in vivo GVT activity of alpha(4)beta(7)(-) donor T cells was preserved. We conclude that the alpha(4)beta(7) integrin is important for the invasion of alloreactive donor T cells into the gut and the subsequent development of intestinal GVHD and overall GVHD morbidity and mortality.
Similar articles
- Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR. Lu SX, et al. PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6. PLoS One. 2011. PMID: 21760897 Free PMC article. - Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver.
Schreder A, Moschovakis GL, Halle S, Schlue J, Lee CW, Schippers A, David S, Bernhardt G, Ganser A, Pabst O, Förster R, Koenecke C. Schreder A, et al. Biol Blood Marrow Transplant. 2015 Dec;21(12):2069-2078. doi: 10.1016/j.bbmt.2015.08.038. Epub 2015 Sep 5. Biol Blood Marrow Transplant. 2015. PMID: 26348893 - Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation.
Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DR, Champlin RE, Molldrem JJ, Ma Q. Wang Y, et al. Biol Blood Marrow Transplant. 2009 Dec;15(12):1513-22. doi: 10.1016/j.bbmt.2009.08.013. Epub 2009 Oct 7. Biol Blood Marrow Transplant. 2009. PMID: 19896074 Free PMC article. - Integrin molecules involved in lymphocyte homing to Peyer's patches.
Holzmann B, Weissman IL. Holzmann B, et al. Immunol Rev. 1989 Apr;108:45-61. doi: 10.1111/j.1600-065x.1989.tb00012.x. Immunol Rev. 1989. PMID: 2670742 Review. - Role of beta7 integrins in intestinal lymphocyte homing and retention.
Gorfu G, Rivera-Nieves J, Ley K. Gorfu G, et al. Curr Mol Med. 2009 Sep;9(7):836-50. doi: 10.2174/156652409789105525. Curr Mol Med. 2009. PMID: 19860663 Free PMC article. Review.
Cited by
- Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease.
Zu Y, Gui R, Li Z, Wang J, Li P, Liu Y, Dong X, Zhou J. Zu Y, et al. Ther Adv Hematol. 2024 Sep 6;15:20406207241276982. doi: 10.1177/20406207241276982. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39247427 Free PMC article. - Evaluation of the Antifibrotic Effects of Drugs Commonly Used in Inflammatory Intestinal Diseases on In Vitro Intestinal Cellular Models.
Artone S, Ciafarone A, Augello FR, Lombardi F, Cifone MG, Palumbo P, Cinque B, Latella G. Artone S, et al. Int J Mol Sci. 2024 Aug 14;25(16):8862. doi: 10.3390/ijms25168862. Int J Mol Sci. 2024. PMID: 39201548 Free PMC article. - Mathematical Modeling of Vedolizumab Treatment's Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients.
D'Ambrosio A, Altomare A, Boscarino T, Gori M, Balestrieri P, Putignani L, Del Chierico F, Carotti S, Cicala M, Guarino MPL, Piemonte V. D'Ambrosio A, et al. Bioengineering (Basel). 2024 Jul 12;11(7):710. doi: 10.3390/bioengineering11070710. Bioengineering (Basel). 2024. PMID: 39061792 Free PMC article. - The effect of ADAMTS13 on graft-versus-host disease.
Li D, Cho MS, Gonzalez-Delgado R, Liang X, Dong JF, Cruz MA, Ma Q, Afshar-Kharghan V. Li D, et al. J Cell Mol Med. 2024 Jul;28(13):e18457. doi: 10.1111/jcmm.18457. J Cell Mol Med. 2024. PMID: 38963011 Free PMC article. - Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
Chen YB, Mohty M, Zeiser R, Teshima T, Jamy O, Maertens J, Purtill D, Chen J, Cao H, Rossiter G, Jansson J, Fløisand Y. Chen YB, et al. Nat Med. 2024 Aug;30(8):2277-2287. doi: 10.1038/s41591-024-03016-4. Epub 2024 Jun 6. Nat Med. 2024. PMID: 38844797 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical